期刊文献+

2-苯氧乙醇对无细胞百日咳原液及无细胞百白破联合疫苗安全性及免疫原性的影响 被引量:5

Effect of 2-Phenoxyethanol on Safety and Immunogenicity of Bulk Acellular Pertussis Vaccine and Acellular DTP
原文传递
导出
摘要 目的探讨2-苯氧乙醇对无细胞百日咳(aP)原液及无细胞百白破联合疫苗(DTaP)安全性及免疫原性的影响。方法分别制备以2-苯氧乙醇和硫柳汞作为防腐剂的aP原液,并配制以2-苯氧乙醇作为防腐剂的DTaP疫苗,对其安全性及免疫原性进行检测,并检测DTaP疫苗中2-苯氧乙醇的抑菌效果。结果分别以2-苯氧乙醇和硫柳汞作为防腐剂制备的aP原液的安全性及免疫原性各项指标比较,差异均无统计学意义(P>0.05);以2-苯氧乙醇作为防腐剂的DTaP疫苗各项检定指标均符合《中国药典》三部(2005版)要求,DTaP疫苗及于37℃放置1个月的DTaP疫苗经无菌检查均合格。结论 2-苯氧乙醇可替代硫柳汞用作DTaP疫苗的防腐剂。 Objective To investigate the effect of 2-phenoxyethanol on safety and immunogenicity of bulk acellular pertussis(aP) vaccine and acellular DTP(DTaP).Methods The bulk of aP was formulated using 2-phenoxyethanol and thimerosal as stabilizers and prepared into DTaP respectively.The safety and immunogenicity of bulk aP and DTaP,as well as the bacteriostatic effect of 2-phenoxyethanol in DTaP,were evaluated.Results The bulks of aP prepared using 2-phenoxyethanol and thimerosal as stabilizers showed no significant difference in safety and immunogenicity(P 0.05).All the indexes of DTaP using 2-phenoxyethanol as stabilizer met the requirements in Chinese Pharmacopoeia(Volume Ⅲ,2005 edition).Both the DTaP before and after storage at 37℃ for one month were qualified in sterility test.Conclusion 2-Phenoxyethanol may be used as a stabilizer of DTaP instead of thimerosal.
出处 《中国生物制品学杂志》 CAS CSCD 2011年第10期1165-1167,共3页 Chinese Journal of Biologicals
关键词 2-苯氧乙醇 无细胞百日咳原液 无细胞百白破联合疫苗 硫柳汞 2-Phenoxyethanol Bulk acellular pertussis vaccine Acellular DTP Thimerosal
  • 相关文献

参考文献9

  • 1周海云(编译),张静(编译),江丽君(审校).有关疫苗防腐剂和神经发育障碍的研究评述[J].国际生物制品学杂志,2007,30(4):176-179. 被引量:2
  • 2Geier DA, Jordan SK, Geier MR. The relative toxicity of com- pounds used as preservatives in vaccines and biologics [J]. Med Sci Monit, 2010, 16 (5): SR21-SR27.
  • 3马霄,赵建荣,田霖,雷殿良.应用RP-HPLC法测定疫苗中2-苯氧乙醇的含量[J].中国生物制品学杂志,2001,14(4):245-246. 被引量:4
  • 4卞传秀,姜述德,杨建勇,孙明波,谢明学,张新文,廖国阳,李卫东.二苯氧乙醇对Sabin株脊髓灰质炎灭活疫苗效力的影响及安全性研究[J].中华实验和临床病毒学杂志,2007,21(1):44-46. 被引量:6
  • 5Wilson M, Stanley A, Bansal G, et al. Effect of phenoxyethanol, chlorhexidine and their combination on'subgingival plaque bacteria [J]. J Antimicrob Chemother, 1990, 25 (6): 921-929.
  • 6Komatsu E, Yamazaki H, Abe K, et al. Influence of temperature on the efficacy of 2-phenoxyethanol as a preservative for adsorbed diphtheria-purified pertussis-tetanus combined vaccine [J]. J Health Sci, 2002, 48 (1): 89-92.
  • 7Buhrer C, Bahr S, Siebert J, et al. Use of 2% 2-phenoxyethanol and 0.1% octenidine as antiseptic in premature newborn infants of 23-26 weeks gestation [J]. J Hosp Infect, 2002, 51 (4): 305-307.
  • 8Lowe I, Southern J. The antimicrobial activity of phenoxyethanol in vaccines [ J ]. Lett Appl Microbiol, 1994, 18 (2) : 115-116.
  • 9Gloriani NG, Srinivasa K, Bock HL, et al. Immunogenicity of HBV vaccine during stated shelf-life [J]. Southeast Asian J Trop Med Public Health, 2010 ,41 (4): 876-882.

二级参考文献10

  • 1中国生物制品标准委员会.中国生物制品规程[M].,2000.118-123,180-183,686-687.
  • 2Davissen EO, Powell HM, Maefarlane JO, Hodgson R, Stone RL,Culbertson CG. The preservation of poliomyelitis vaccine with stabilized merthiolate. J Lab Clin Med. 1956,47:8-19.
  • 3Hessel L. Mercury in vaccines. Bull Acad Natl Med, 2003, 187:1501-1510.
  • 4Wilson M, Stanley A. Bansal G, Newman H. Effect of phenoxyethanol,chlorhexidine and their combination on subgingival plaque bacteria. J Antimicrob Chemother. 1990,25:921-919.
  • 5Lowe I. Southern J. The antimicrobial activity of phenoxyethanol in vaccines. Lett Appl Microbiol. 1994,18 : 115-116.
  • 6Buhrer C, Bahr S, Siebert J, Wettstein R, Geffers C, Obladen M. Use of 2% 2-phenoxyethanol and 0.1% octenidine as antiseptic in premature newborn infants of 23-26 weeks gestation J Hosp Infect, 2002,51:305.
  • 7John Clements C, McIntyre PB. When science is not enough-a risk/benefit profile of thiomersal-containing vaccines. Expert Opin Drug Saf, 2006,5 (1) : 17-29.
  • 8Andrews N,Miller E,Grant A, et al. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal associa tion. Pediatrics,2004,114(3) :584-591.
  • 9Bigham M,Copes R. Thiomersal in vaccine:balancing the risk of adverse effects with the risk of vaccine-preventable disease. Drug Saf. 2005,28(2):89-101.
  • 10马丽莉.使用口服脊髓灰质炎减毒活疫苗的国家引入注射用脊髓灰质炎灭活疫苗[J].中国计划免疫,2003,9(6):378-378. 被引量:5

共引文献9

同被引文献54

引证文献5

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部